Autor(es): Loureiro,Camila Marcelino ; Corsi-Zuelli,Fabiana ; Fachim,Helene Aparecida ; Shuhama,Rosana ; Chagas,Natália Mota de Souza ; Menezes,Paulo Rossi ; Del-Ben,Cristina Marta ; Louzada-Junior,Paulo
Data: 2021
Origem: Oasisbr
Assunto(s): Antibodies anti-NMDAR; Bipolar disorder; Differential diagnosis; First-episode psychosis
Abstract We investigated the feasibility of including plasma anti-NMDAR antibody screening in the assessment of first-episode psychosis patients in an early intervention programme in the Southern hemisphere. Anti-NMDAR IgG antibodies were assessed by ELISA in 166 patients (64.0% men), 166 matched population-based controls and 76 patients’ siblings (30.3% men). Fisher’s exact test and ANOVA were performed. Positive anti-NMDAR antibody patients were more often observed in bipolar disorder (10.0%) than schizophrenia (2.4%) or psychotic depression (3.1%), although no significant differences were observed. Our results are not conclusive regarding the inclusion of plasma anti-NMDAR IgG antibodies in differential diagnostic protocols for psychosis.
